5-Amino-1MQ for Weight Loss: Mouse Data vs Marketing

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme involved in cellular NAD+ and methyl-group metabolism. It is not a peptide, despite frequently being sold alongside peptides in research-chemical marketplaces. For the mechanism itself, see our NNMT inhibition mechanism explainer; for basic identity and formulation questions, see what is 5-amino-1MQ.

This page answers one narrow question: what does the actual weight-related evidence show, and where does it stop.

What did the mouse studies actually measure?

The foundational obesity work used NNMT inhibitors, including compounds structurally related to or identical with 5-amino-1MQ, in diet-induced obese (DIO) mouse models. Researchers fed mice a high-fat diet to establish obesity, then dosed them with an NNMT inhibitor and tracked body weight, fat mass, and metabolic markers over several weeks.

One key study reported that a selective, membrane-permeable NNMT inhibitor reversed high-fat-diet-induced obesity in mice, with reductions in body weight and adiposity accompanying enzyme inhibition (PMID 29155147). A related tricyclic small-molecule inhibitor program reported similar metabolic-disorder-relevant effects in mouse models (PMID 36104373, PMID 29483571). More recent work links NNMT inhibition to mitigation of obesity-related metabolic dysfunction, again in animal models (PMID 39161060).

These are legitimate, peer-reviewed findings. They are also, without exception, rodent findings. None of the cited papers report a randomized controlled trial, an open-label human pilot, or even a human pharmacokinetic study of 5-amino-1MQ dosed for weight loss.

Is there a plausible mechanism, or just a correlation?

The mechanistic story has some coherence. NNMT sits at a metabolic crossroads: it consumes NAD+ and methyl donors (via SAM) to methylate nicotinamide, and its activity is elevated in adipose tissue in obesity and metabolic syndrome (PMID 33453420, PMID 34368359). NNMT expression in adipocytes appears responsive to glucose availability (PMID 32112869), and NNMT is induced during beige adipogenesis in a depot-specific manner (PMID 34699038), which is one proposed link between the enzyme and thermogenic fat metabolism. Reviews describe NNMT as a candidate therapeutic target for metabolic syndrome on this basis (PMID 38919254, PMID 39604638).

A plausible mechanism is not evidence of a clinical effect. Metabolic pathways that look clean in a mouse adipocyte often behave differently in a person with a decade of insulin resistance, different NNMT tissue distribution, and a different diet history. The mechanism review literature itself frames NNMT as a target under investigation, not a validated human intervention point (PMID 39604638).

What do we know about getting 5-amino-1MQ into the body at all?

This is where the evidence gets thinner still. A pharmacokinetic study developed and validated an LC-MS/MS assay for 5-amino-1MQ and used it to assess oral bioavailability, but the work was conducted in rat plasma, not human subjects (PMID 34304009). That means even the basic question of how much orally dosed 5-amino-1MQ reaches systemic circulation in a person, and over what time course, has not been answered in the literature we have access to. For a closer look at what the rat PK data does and does not tell you, see oral bioavailability.

Without human PK data, any dosing protocol circulating online is not derived from clinical dose-finding. It is derived from mouse mg/kg doses scaled by body weight, a method that frequently overestimates or underestimates the human-equivalent effect because absorption, metabolism, and target engagement do not scale linearly across species. See dosing claims for how these numbers are typically generated and why that matters.

How does this compare to NNMT-adjacent compounds like N1-methylnicotinamide?

A related but distinct compound, N1-methylnicotinamide, has been studied as a potential dietary supplement for athletes, with human relevance discussed in the literature (PMID 35152860). This is a different molecule from 5-amino-1MQ (it is a downstream metabolite of the NNMT reaction, not an inhibitor of the enzyme), and its evidence base should not be borrowed to support claims about 5-amino-1MQ. Conflating adjacent NNMT-pathway compounds is a common marketing shortcut worth watching for.

What is established, what is plausible, and what is not established

Established (animal data, peer-reviewed): NNMT inhibition reduces weight gain and fat mass in diet-induced obese mice over a period of weeks, across multiple independent inhibitor compounds (PMID 29155147, PMID 36104373, PMID 39161060). NNMT is upregulated in metabolically relevant tissue in obesity models and responds to nutrient availability (PMID 32112869, PMID 34699038).

Plausible but unproven in humans: That NNMT inhibition via 5-amino-1MQ specifically would produce comparable weight or fat-mass changes in people. That any human-equivalent dose can be reliably derived from mouse dosing. That oral 5-amino-1MQ achieves meaningful systemic exposure in humans at commonly sold doses.

Not established: Any human efficacy, any human safety profile, any validated human dose, and any FDA-recognized use. 5-amino-1MQ has no FDA-approved application for any indication and is not on the FDA's 503A bulks list for compounding, meaning it lacks a recognized regulatory pathway for compounded human use. See the FDA status page and the FDA Peptide Status Tracker for current regulatory framing, and verify status directly with FDA sources given how quickly these listings can change.

A framework for reading any "5-amino-1MQ works" claim

Before accepting a claim about 5-amino-1MQ and weight loss, run it through four checks:

1. Species check. Does the cited study use human subjects, or mouse/rat models? If the source is not specified, assume animal until proven otherwise; as of this writing every weight-related finding in the literature is rodent-derived.
2. Compound check. Is the study testing 5-amino-1MQ itself, or a structurally related NNMT inhibitor, or a downstream metabolite like N1-methylnicotinamide? These are not interchangeable.
3. Endpoint check. Is the reported outcome body weight and fat mass, or an upstream biomarker (enzyme activity, gene expression) being presented as if it were a weight outcome?
4. Dose-translation check. Is the human dose being recommended derived from a validated human PK study, or extrapolated from a mouse mg/kg dose with no bridging data? Given that even oral bioavailability has only been characterized in rats (PMID 34304009), any confident human dosing claim fails this check today.

A claim that fails two or more of these checks is marketing framed as evidence, not a clinical finding.

Where this leaves someone considering it

If you are weighing 5-amino-1MQ against an FDA-approved option, the comparison is asymmetric: GLP-1 receptor agonists have large randomized human trials behind their weight-loss indications, while 5-amino-1MQ has none. See 5-amino-1MQ vs GLP-1 medications for that comparison in more depth, and side effects and safety for what little safety signal exists.

Anyone currently using 5-amino-1MQ who develops unexplained symptoms, jaundice, unusual fatigue, or signs of liver or kidney dysfunction should stop the product and seek medical evaluation promptly; because no human trial has characterized its adverse-effect profile, unusual symptoms cannot be attributed to it with any confidence, which is itself a reason for caution rather than reassurance.